Introduction
Sperm motility is one of the most important parameters for predicting fertility outcomes [
1,
2]. Motile sperm concentration (MSC), a key measurement derived from semen analysis, integrates sperm concentration and motility into a single clinically relevant parameter. Standard semen analysis, performed according to World Health Organization (WHO) guidance, remains the most widely used approach [
3]. However, sperm motility assessment is technically challenging because it requires skilled personnel, specialized equipment, and substantial time. Microscopic examinations based on manual counting are subject to considerable interobserver variability, and result accuracy depends largely on examiner expertise [
4]. Conventional semen analysis therefore has important practical limitations, particularly in settings with limited laboratory resources.
To improve accessibility and convenience, several home-based semen testing systems have recently been developed. Smartphone-based platforms are relatively affordable and easy to use because they use the built-in camera of a mobile device, although computer- and laptop-based systems are also available. These tools may help men assess fertility status earlier and with fewer logistical barriers [
5-
7]. In addition, semen samples collected at home may have higher sperm concentration and motility than samples collected in clinical settings [
8].
The YO Home Sperm Test is a smartphone-based semen analysis platform approved by the U.S. Food and Drug Administration (FDA) [
5,
9]. The system combines optical imaging technology with proprietary image-processing algorithms to evaluate sperm motility. A miniature microscope attachment allows the smartphone camera to capture videos of sperm movement, and the software analyzes changes in pixel intensity generated by moving spermatozoa to estimate MSC. This approach provides a rapid, user-friendly alternative to conventional laboratory-based semen analysis while maintaining analytical performance suitable for fertility screening [
5].
This study evaluated the agreement between MSC measurements obtained with the YO Home Sperm Test and those generated by standard laboratory methods, including computer-assisted semen analysis (CASA) and manual semen analysis. Because MSC incorporates both sperm concentration and motility, it may provide clinically useful information about male fertility potential.
In Thailand, both home sperm testing and CASA are currently available. Our results may be particularly useful as these tools become more widely available in developing countries.
Methods
The study protocol was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB 0366/2564). Written informed consent was obtained from all participants. Semen samples were obtained from the Reproductive Medicine Unit and included samples from both patients undergoing fertility evaluation and volunteers. The sample size was calculated using the methodology reported by Agarwal et al. [
9]. Assuming an expected intraclass correlation coefficient (ICC) of 0.90, a minimally acceptable ICC of 0.80, α=0.05, and β=0.20, the minimum required sample size was 28 participants. To improve precision and account for potential exclusions, 40 participants were enrolled.
A total of 40 semen samples were collected by masturbation into clean, wide-mouthed plastic containers after 2 to 7 days of sexual abstinence. Samples were maintained at 37 °C and allowed to liquefy before analysis. Semen volume and sperm motility were initially assessed using the wet preparation method described in the WHO fifth-edition manual [
3]. Each sample was divided equally into three aliquots and analyzed separately by manual semen analysis, CASA, and the YO Home Sperm Test. All assessments were performed immediately after liquefaction to minimize time-dependent changes in sperm motility.
Manual semen analysis was performed using a Makler chamber. A 5-µL aliquot of well-mixed, undiluted semen was placed in the center of the chamber to determine sperm concentration. The chamber contains a 1-mm² grid subdivided into 100 squares, and sperm concentration was calculated from the number of sperm heads counted in 10 designated squares. For motility assessment, 5 µL of a well-mixed specimen was loaded into the Makler chamber, allowing sperm to move freely within the observation field [
10]. The slide was examined using phase-contrast optics at 200× magnification. Approximately 200 spermatozoa were immediately counted and classified as progressive, non-progressive, or immotile. Sperm vitality was assessed using eosin-nigrosin staining, which enhances contrast between sperm heads and the background, and slides were examined under bright-field microscopy [
3]. Sperm concentration and vitality were independently assessed by two experienced observers (Pimpitcha Puangsricharoen and Jiraporn Ngeamvijavat), and results were compared on a cell-by-cell basis.
CASA was performed using the Hamilton Thorne Integrated Visual Optical System motility analyzer (version 12.0; Hamilton Thorne) (
Figure 1). Samples were loaded into a fixed-depth Makler chamber using a 5-µL aliquot. The system recorded images at 60 images/sec. Sperm cells could swim freely along the x- and y-axes but were limited in the z-axis. Total sperm concentration (million/mL), total motility (%), and progressive motility (%) were calculated automatically. Sperm movement was categorized as rapid progressive (≥25 µm/sec), slow progressive (<25 and ≥5 µm/sec), non-progressive motile (<5 µm/sec), or immotile [
11].
For the YO Home Sperm Test, manufacturer-provided liquefaction powder was added immediately after sample collection. Liquefied semen was placed on a fixed-coverslip testing slide until the loading area was filled. The slide was then inserted into the smartphone-mounted optical attachment. Results were reported as a YO Score, a proprietary semi-quantitative index representing MSC percentile ranges derived from WHO reference populations (Medical Electronic Systems Ltd., unpublished technical documentation) [
9]. MSC values obtained from manual semen analysis, CASA, and the YO Home Sperm Test were compared.
1. Device overview
The principle of home mobile sperm testing is based on video recording of sperm movement, in which alterations in sperm movement are interpreted as pixel-level light-signal changes and converted into MSC by the device algorithm. The YO Home Sperm Test received U.S. FDA approval in 2016. It can be used with iPhone, Galaxy, and macOS devices. The device kit includes a plastic cup for sample collection, liquefaction powder, fixed-volume transfer pipettes, and a plastic test slide with a fixed coverslip (
Figure 2).
A clip is attached to the top of a smartphone with a camera resolution of 1,920×1,080 pixels or higher. Backlight from the smartphone illuminates the sample on a fixed-coverslip slide and projects the image through two angled mirrors based on the principle of light reflection. The light is then diverted to a ball lens at 100× magnification and reaches the charge-coupled device of the smartphone. During testing, a 30-second video is recorded, and proprietary image-processing algorithms analyze temporal changes in pixel intensity generated by moving spermatozoa. These optical signals are converted into estimates of MSC (
Figure 3). In this study, testing was performed using an iPhone 8 Plus equipped with a 12-megapixel camera and the YO application (version 1.0) downloaded from the App Store.
After approximately 2 minutes of analysis, the result was displayed as moderate/normal MSC (≥6.0 million/mL) or low MSC (<6.0 million/mL). The YO Score reports results in 10–90+ MSC percentile levels based on the WHO fifth edition [
9].
2. Statistical analysis
Demographic data are presented as mean±standard deviation for normally distributed variables. Non-normally distributed variables are presented as median (range). The ICC was used to evaluate agreement in MSC between methods. ICC values are reported on a scale from 0 to 1.0. ICC values of <0.5, 0.5–0.75, 0.75–0.90, and >0.90 were interpreted as indicating poor, moderate, good, and excellent reliability, respectively. An exploratory post hoc subgroup analysis was performed using an MSC threshold of 30×10⁶/mL. This threshold was selected based on visual inspection of agreement plots and the categorical reporting structure of the YO Home Sperm Test, which suggested increased variability at higher MSC values. Statistical analyses were performed using SPSS version 22.0 (IBM Co.).
Results
Table 1 summarizes the baseline characteristics of the 40 participants. The mean age was 36±6.1 years, and the mean body mass index was 22.5±2.8 kg/m². On manual semen analysis, mean semen volume was 2.3±0.7 mL, median sperm concentration was 41.8×10⁶/mL (range, 8 to 114), median sperm motility was 44.8% (range, 24% to 71%), and median MSC was 13.9×10⁶/mL (range, 2 to 61).
Table 2 summarizes the CASA and YO Home Sperm Test results. With CASA, median sperm concentration was 18.6×10⁶/mL (range, 4 to 75), median sperm motility was 72.6% (range, 23.1% to 91.6%), and median MSC was 13.2×10⁶/mL (range, 0.4 to 63.8). The median YO Home Sperm Test score was 20 (range, 0 to 60).
Comparison of MSC among the three methods demonstrated significant agreement (
p<0.01), with an overall ICC of 0.902. Agreement between manual semen analysis and the YO Home Sperm Test yielded an ICC of 0.815 (95% confidence interval [CI], 0.651 to 0.902) (
Figure 4). Agreement between manual semen analysis and CASA yielded an ICC of 0.793 (95% CI, 0.608 to 0.890) (
Figure 5), whereas agreement between the YO Home Sperm Test and CASA yielded an ICC of 0.944 (95% CI, 0.894 to 0.970) (
Figure 6). Agreement between methods was further evaluated using Bland–Altman analysis (
Figures 4-
6). Visual inspection of the scatter plots and Bland–Altman plots suggested closer agreement at lower MSC values and greater variability at higher concentrations.
In the exploratory subgroup analysis of samples with MSC <30×10⁶/mL by manual semen analysis, agreement between manual semen analysis and the YO Home Sperm Test yielded an ICC of 0.675 (95% CI, 0.317 to 0.845) (
Figure 7). For the comparison between the YO Home Sperm Test and CASA, the subgroup with MSC <30×10⁶/mL yielded an ICC of 0.930 (95% CI, 0.854 to 0.967), whereas the subgroup with MSC ≥30×10⁶/mL yielded an ICC of 0.845 (95% CI, 0.378 to 0.962) (
Figure 8).
Discussion
Semen analysis is central to the evaluation of male infertility. Laboratory-based methods, including manual semen analysis and CASA, are commonly used. However, these methods require trained personnel and laboratory infrastructure and may be affected by subjectivity and human error [
3,
12]. CASA and other automated sperm analyzers, such as the Sperm Quality Analyzer (SQA-Vision; Medical Electronic Systems), offer higher specificity but are limited by cost, size, and restricted field of view, which may constrain their use, particularly in field studies [
5].
A study of 105 men demonstrated significant correlations in total sperm concentration and motility among SQA-V, manual semen analysis, and CASA. These findings support the comparative reliability of different semen analysis methods [
13].
The introduction of home-based sperm testing devices has improved privacy and may reduce stress during fertility evaluation. These devices have become more widely used, although most measure only sperm concentration and do not assess key parameters such as motility [
7,
14-
17]. In the present study, we used the YO device, one of the few U.S. FDA-approved home sperm testing systems that reports MSC.
To our knowledge, limited data are available on the agreement among smartphone-based home sperm testing, manual semen analysis, and CASA. The present study was designed to address this evidence gap. A notable finding was the stronger agreement between home sperm testing and CASA, possibly because both methods use more objective analytic approaches than the manual counts required in standard semen analysis. This finding suggests that home sperm testing may be a viable screening alternative, particularly for men with fertility concerns.
Previous studies have evaluated the accuracy and agreement of home sperm testing with professional analyzers such as SQA-Vision. These studies have consistently reported strong correlations and high precision in MSC measurements, supporting the reliability of home sperm testing [
9,
18].
In 2018, Agarwal et al. [
9] analyzed 144 aliquots from 24 sperm donors to compare MSC values measured by the YO device on Galaxy and iPhone platforms with those measured by the SQA-Vision analyzer. SQA-Vision uses optoelectronics, computer algorithms, and video microscopy. They found that MSC measured by YO correlated strongly with SQA results, with an ICC of 0.9309 [
9]. After testing, data were displayed as “normal” or “low” MSC using a cutoff of 6 million. Several studies have supported this parameter. A report of 1,082 fertile men showed an MSC threshold of 4.0×10⁶/mL [
19]. Redmon et al. [
20] further characterized semen parameters in 763 fertile U.S. men, reporting a mean sperm concentration of 60×10⁶/mL and mean motility of 51%, although MSC was not directly reported.
Honig et al. [
18] compared the YO mobile device with SQA in 2019 and reported high precision for MSC calculation. In that study, 316 semen samples were analyzed. SQA was used as the comparator because it had shown a Spearman coefficient of 0.96 with manual analysis. The device demonstrated high positive predictive agreement (97.6%) and negative predictive agreement (97%). Between trained professionals and SQA-V, MSC results showed an accuracy of 97.3% [
18].
Compared with laboratory-based CASA systems, which require specialized equipment and trained personnel, smartphone-based home tests are substantially less expensive and more accessible [
17,
21]. This may be particularly relevant in resource-limited settings where access to fertility laboratories is restricted. Agreement between the YO Home Sperm Test and CASA appeared stronger at lower MSC values than at higher concentrations. Notably, the 30×10⁶/mL threshold was identified through an exploratory
post hoc analysis and was not prespecified in the study design. Therefore, this finding should be considered hypothesis-generating and requires validation in larger independent cohorts. This pattern may reflect the semi-quantitative nature of the device, which reports MSC values in discrete categories rather than as continuous measurements. Importantly, the primary clinical role of home sperm testing devices is screening for impaired semen quality. Therefore, reduced precision at higher MSC values may have limited clinical significance, because men with values substantially above clinically relevant thresholds would generally not be reclassified into different clinical management categories.
Male infertility is multifactorial, and semen parameters such as motility contribute to fertility assessment. Evidence suggests that combining motility and concentration data provides a more accurate assessment than morphology alone [
15,
22,
23]. However, most home semen testing devices do not provide a comprehensive semen analysis; many report sperm concentration alone, whereas some newer devices provide additional or composite measures such as motile sperm concentration.
Several limitations should be considered. First, the study population consisted primarily of Asian men with a mean age of 36 years. Although this provides useful information for the target population, it may limit the generalizability of the findings to other ethnic and geographic populations. Second, the testing sequence was not randomized. Although all analyses were performed promptly after liquefaction, sperm motility may decline over time after ejaculation, and minor time-dependent changes may have contributed to differences between methods. Third, only a single smartphone model (iPhone 8 Plus) was evaluated. Differences in camera sensors, image-processing pipelines, and operating systems may influence performance across smartphone models. Although previous validation studies have demonstrated high accuracy across both iPhone and Android platforms, additional studies examining inter-device variability and compatibility across smartphone platforms are warranted [
24].
User error and variability in sample handling during home testing may also affect results. Consequently, home sperm testing should currently be considered a screening tool rather than a replacement for comprehensive laboratory semen analysis [
6]. Differences in sample handling, device operation, and result interpretation may contribute to variability when the test is used outside controlled laboratory settings. Future studies should investigate strategies to minimize these factors through standardized user instructions and improved device design.
Future home sperm testing platforms may benefit from reporting additional semen parameters, including progressive motility and other detailed kinetic measurements, to enhance clinical utility. Although the present study focused on MSC, other semen parameters, such as sperm morphology and DNA fragmentation, are also important components of fertility assessment and should be considered in future device development and validation studies [
6].
Further research is needed to determine how home sperm testing can be integrated into existing fertility assessment protocols. Future studies should compare these devices with standard clinical practice in terms of diagnostic performance, convenience, patient acceptability, and cost-effectiveness. In addition, studies evaluating different MSC concentration ranges, real-world patient self-testing, and long-term reproductive outcomes, including pregnancy rates, would provide valuable insight into the clinical utility and reliability of home sperm testing devices.
In this study, the YO Home Sperm Test showed agreement with standard manual semen analysis and CASA for the assessment of MSC. These findings support its potential role as a convenient, private, and accessible screening tool for the initial evaluation of male fertility. The device may facilitate earlier fertility assessment and improve participation in male infertility evaluation. Further studies are needed to validate these findings in larger and more diverse populations and to assess performance across different smartphone platforms and clinical settings.